Browsing by Author Blauvelt, Andrew
Showing results 1 to 2 of 2
| Issue Date | Title | Author(s) |
| 2016-07 | Secukinumab exhibits low immunogenicity during 104 weeks of treatment in subjects with moderate to severe plaque psoriasis. | Sinclair, Rodney; Reich, K.; Blauvelt, Andrew; Warren, R. B.; Szepietowski, J. C.; Sigurgeirsson, B.; Langley, R. G. B.; Tyring, S.; Messina, I.; Fox, T.; Papavassilis, C.; Bruin, G. | |
| 2017-07 | Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. | Sinclair, Rodney; Reich, Kristian; Papp, Kim; Blauvelt, Andrew; Tyring, Stephen; Thaçi, Diamant; Nograles, Kristine; Mehta, Anish; Cichanowitz, Nicole; Li, Qing; Liu, Kenneth; La Rosa, Carmen; Green, Stuart; Kimball, Alexa | |
